Imperial College London
Portrait Picture

DrAnandShah

Faculty of Medicine, School of Public Health

Honorary Clinical Senior Lecturer
 
 
 
//

Contact

 

s.anand

 
 
//

Location

 

Fulham RoadRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{RECOVERY:2022:10.1016/S0140-6736(22)01109-6,
author = {RECOVERY, Collaborative Group},
doi = {10.1016/S0140-6736(22)01109-6},
journal = {The Lancet},
pages = {359--368},
title = {Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.},
url = {http://dx.doi.org/10.1016/S0140-6736(22)01109-6},
volume = {400},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1-2 inhibitor, for the treatment of patients admitted to hospital with COVID-19. METHODS: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple possible treatments in patients hospitalised with COVID-19 in the UK. Eligible and consenting patients were randomly allocated (1:1) to either usual standard of care alone (usual care group) or usual care plus baricitinib 4 mg once daily by mouth for 10 days or until discharge if sooner (baricitinib group). The primary outcome was 28-day mortality assessed in the intention-to-treat population. A meta-analysis was done, which included the results from the RECOVERY trial and all previous randomised controlled trials of baricitinib or other JAK inhibitor in patients hospitalised with COVID-19. The RECOVERY trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936) and is ongoing. FINDINGS: Between Feb 2 and Dec 29, 2021, from 10852 enrolled, 8156 patients were randomly allocated to receive usual care plus baricitinib versus usual care alone. At randomisation, 95% of patients were receiving corticosteroids and 23% were receiving tocilizumab (with planned use within the next 24 h recorded for a further 9%). Overall, 514 (12%) of 4148 patients allocated to baricitinib versus 546 (14%) of 4008 patients allocated to usual care died within 28 days (age-adjusted rate ratio 0·87; 95% CI 0·77-0·99; p=0·028). This 13% proportional reduction in mortality was somewhat smaller than that seen in a meta-analysis of eight previous trials of a JAK inhibitor (involving 3732 patients and 425 deaths), in which allocation to a JAK inhibitor was associated with a 43% proportional reduction in mortality (rate ratio 0·57; 95% CI 0·45-0·72). Including the results from RECOVERY in an updated meta-analysis of all nine completed t
AU  - RECOVERY,Collaborative Group
DO  - 10.1016/S0140-6736(22)01109-6
EP  - 368
PY  - 2022///
SN  - 0140-6736
SP  - 359
TI  - Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
T2  - The Lancet
UR  - http://dx.doi.org/10.1016/S0140-6736(22)01109-6
UR  - https://www.ncbi.nlm.nih.gov/pubmed/35908569
UR  - http://hdl.handle.net/10044/1/100187
VL  - 400
ER  -
Download